We believe Bayer has a Morningstar economic moat rating of none. Despite some competitive advantages in its healthcare and crop science businesses when analyzed in isolation, we think the company's returns on invested capital have been weighed down by its $63 billion acquisition of Monsanto in 2018 and will remain below the cost of capital over the next 10 years or so.